Beam Therapeutics Inc. Capital Expenditures
Beam Therapeutics Inc. (BEAM) reported Capital Expenditures of $4.65 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-04
- Beam Therapeutics Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $2.41M, a 23.02% decline year-over-year.
- Beam Therapeutics Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $2.23M, a 27.18% decline year-over-year.
- Beam Therapeutics Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $3.73M, a 25.72% increase year-over-year.
- Beam Therapeutics Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $5.01M, a 217.76% increase year-over-year.
- Beam Therapeutics Inc. payments to acquire property, plant, and equipment for fiscal 2025 was $14.95M, a 67.07% increase from fiscal 2024.
- Beam Therapeutics Inc. payments to acquire property, plant, and equipment for fiscal 2024 was $8.95M, a 73.48% decline from fiscal 2023.
- Beam Therapeutics Inc. payments to acquire property, plant, and equipment for fiscal 2023 was $33.73M, a 31.09% decline from fiscal 2022.
- Beam Therapeutics Inc. payments to acquire property, plant, and equipment for fiscal 2022 was $48.95M, a 4.57% increase from fiscal 2021.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $4.65M 10-Q · filed 2026-08-04 | $8.38M derived: sum of 3 quarters · filed 2026-08-04 | $13.39M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $2.23M 10-Q · filed 2026-05-07 | $5.97M derived: sum of 2 quarters · filed 2026-05-07 | $10.98M derived: sum of 3 quarters · filed 2026-05-07 | $14.11M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $3.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $8.74M derived: sum of 2 quarters · filed 2026-02-24 | $11.88M derived: sum of 3 quarters · filed 2026-08-04 | $14.95M 10-K · filed 2026-02-24 |
| 2025-09-30 | $5.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $8.15M derived: sum of 2 quarters · filed 2026-08-04 | $11.21M 10-Q · filed 2025-11-04 | $14.18M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $3.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $6.20M 10-Q · filed 2026-08-04 | $9.17M derived: sum of 3 quarters · filed 2026-08-04 | $10.75M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $3.06M 10-Q · filed 2026-05-07 | $6.04M derived: sum of 2 quarters · filed 2026-05-07 | $7.61M derived: sum of 3 quarters · filed 2026-05-07 | $9.57M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $2.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $4.55M derived: sum of 2 quarters · filed 2026-02-24 | $6.51M derived: sum of 3 quarters · filed 2026-02-24 | $8.95M 10-K · filed 2026-02-24 |
| 2024-09-30 | $1.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $3.54M derived: sum of 2 quarters · filed 2025-11-04 | $5.98M 10-Q · filed 2025-11-04 | $9.56M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $1.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $4.40M 10-Q · filed 2025-08-05 | $7.99M derived: sum of 3 quarters · filed 2026-02-24 | $15.94M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $2.44M 10-Q · filed 2025-05-06 | $6.03M derived: sum of 2 quarters · filed 2026-02-24 | $13.97M derived: sum of 3 quarters · filed 2026-02-24 | $30.15M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $3.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $11.54M derived: sum of 2 quarters · filed 2026-02-24 | $27.71M derived: sum of 3 quarters · filed 2026-02-24 | $33.73M 10-K · filed 2026-02-24 |
| 2023-09-30 | $7.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $24.13M derived: sum of 2 quarters · filed 2024-11-05 | $30.14M 10-Q · filed 2024-11-05 | $38.40M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $16.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $22.20M 10-Q · filed 2024-08-06 | $30.46M derived: sum of 3 quarters · filed 2025-02-25 | $42.24M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $6.02M 10-Q · filed 2024-05-07 | $14.28M derived: sum of 2 quarters · filed 2025-02-25 | $26.07M derived: sum of 3 quarters · filed 2025-02-25 | $47.71M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $8.26M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $20.05M derived: sum of 2 quarters · filed 2025-02-25 | $41.69M derived: sum of 3 quarters · filed 2025-02-25 | $48.95M 10-K · filed 2025-02-25 |
| 2022-09-30 | $11.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $33.43M derived: sum of 2 quarters · filed 2023-11-08 | $40.69M 10-Q · filed 2023-11-08 | $54.06M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $21.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $28.90M 10-Q · filed 2023-08-08 | $42.27M derived: sum of 3 quarters · filed 2024-02-27 | $48.05M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $7.26M 10-Q · filed 2023-05-10 | $20.63M derived: sum of 2 quarters · filed 2024-02-27 | $26.41M derived: sum of 3 quarters · filed 2024-02-27 | $42.59M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $13.37M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $19.15M derived: sum of 2 quarters · filed 2024-02-27 | $35.33M derived: sum of 3 quarters · filed 2024-02-27 | $46.81M 10-K · filed 2024-02-27 |
| 2021-09-30 | $5.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $21.96M derived: sum of 2 quarters · filed 2022-11-07 | $33.44M 10-Q · filed 2022-11-07 | $41.57M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $16.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $27.66M 10-Q · filed 2022-08-09 | $35.79M derived: sum of 3 quarters · filed 2023-02-28 | $38.61M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $11.48M 10-Q · filed 2022-05-09 | $19.60M derived: sum of 2 quarters · filed 2023-02-28 | $22.42M derived: sum of 3 quarters · filed 2023-02-28 | $24.79M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $8.13M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $10.94M derived: sum of 2 quarters · filed 2023-02-28 | $13.31M derived: sum of 3 quarters · filed 2023-02-28 | $16.36M 10-K · filed 2023-02-28 |
| 2020-09-30 | $2.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $5.19M derived: sum of 2 quarters · filed 2021-11-08 | $8.23M 10-Q · filed 2021-11-08 | $10.39M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $2.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $5.41M 10-Q · filed 2021-08-10 | $7.57M derived: sum of 3 quarters · filed 2022-02-28 | $8.99M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $3.05M 10-Q · filed 2021-05-11 | $5.21M derived: sum of 2 quarters · filed 2022-02-28 | $6.63M derived: sum of 3 quarters · filed 2022-02-28 | $13.21M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $2.16M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $3.58M derived: sum of 2 quarters · filed 2022-02-28 | $10.16M derived: sum of 3 quarters · filed 2022-02-28 | $12.52M 10-K · filed 2022-02-28 |
| 2019-09-30 | $1.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $8.00M derived: sum of 2 quarters · filed 2020-11-10 | $10.36M 10-Q · filed 2020-11-10 | |
| 2019-06-30 | $6.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | $8.94M 10-Q · filed 2020-08-12 | ||
| 2019-03-31 | $2.35M 10-Q · filed 2020-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |